By 
NVOS Stock price prediction, news& historical data
Key Takeaways:
- NVOS operates in Healthcare Services and Product Sales, offering primary care and wellness products.
- Assess your investment strategy and cash flow when considering NVOS stock.
- Recent news: NVOS shares rose 19% post-acquisition approval.
- NVOS has a significant collaboration in India with expansion plans. Please note our predictions are for reference, suggesting a potential 73.649% stock increase to $1.9275 by December 24, 2024.
Are you interested in investing in the NVOS Stock lately? Do you want to know everything about this stock, like its past performance, future price, and recent news? If so, you’re in the right place!
Firstly, NVOS operates in two areas: Healthcare Services and Product Sales. The company is called Novo Integrated Sciences Inc. They and their subsidiaries provide multidisciplinary primary care.
They also make various wellness products and services. To get the NVOS stock forecast, we need more information about the company.
What is NVOS company all about?
Novo Integrated Sciences, Inc. (NVOS) operates as a healthcare company located in Bellevue, Washington. It’s important to note that this information is intended solely for reference and should not be considered as an investment recommendation.
The company’s core focus lies in delivering a comprehensive spectrum of healthcare services. These services encompass the following:
- Physiotherapy
- Chiropractic care
- Occupational therapy
- Laser therapeutics
- Massage therapy
- Acupuncture
- Chiropody
- Neurological functions
- Kinesiology
- Dental services
- Eldercare.
Novo Integrated Sciences provides an extensive array of offerings, encompassing evaluation, therapy, supervision, recovery, and precaution. These services are accessible through their system of clinics, associate clinics, senior residences, and extended care facilities.
What is NVOS stock, and should you consider it?
NVOS stock can be a powerful stock and an investment option to consider. It’s important to understand that investing in stocks like NVOS can be both short-term and long-term. You should assess your investment strategy and goals carefully.
One key factor is the company’s cash flow, which can impact the stock’s performance. It’s advisable to analyze this aspect before making any investment decisions related to NVOS stock.
NVOS Stock News – Get the latest information
On Monday afternoon, healthcare stocks showed gains. The NYSE Health Care Index increased by 0.1%, while the Health Care Select Sector SPDR Fund (XLV) rose by 0.2%. The iShares Biotechnology ETF (IBB) also saw a 0.7% increase.
In corporate updates, Alterity Therapeutics (ATHE) reported promising results for its ATH434 treatment in a Parkinson’s disease model, leading to a doubling of its stock value.
Novo Integrated Sciences (NVOS) experienced a 19% stock surge after receiving approval from the US District Court for the Central District of California for its $60 million acquisition of the Ophir Collection, which includes 43 gemstones.
EyePoint Pharmaceuticals (EYPT) nearly tripled its stock value following a successful phase 2 trial of EYP-1901 for wet age-related macular degeneration.
Additionally, 89bio (ETNB) gained 7.5% as it progressed into a phase 3 program for pegozafermin in nonalcoholic steatohepatitis after a positive meeting with the US Food and Drug Administration.
Novo Integrated Sciences Enters Master Collaboration Agreement with Psychocare Health
Novo Integrated Sciences has signed a notable Master Collaboration Accord with Psychocare Health Pvt. Ltd. in India. This partnership signifies the commencement of an initiative to introduce cutting-edge healthcare goods and technologies in the Indian marketplace.
Novo Integrated Sciences intends to expand these healthcare offerings to North America, as articulated in their official declaration.
The initial phase of this three-year agreement permits potential extension by mutual agreement. Psychocare Health Pvt. Ltd. and Novo will initially prioritize the launch of items connected to the central nervous system, gastrointestinal health, and protein supplements.
Find the NVOS stock statistics and analysis.
Here are the latest statistics of the stock as of December 25 2023:
- NVOS stock price: $1.11 -$0.01(-0.89%)
- Day’s Range: $1.06 – $1.13
- 52-Week Range: $0.70 – $5.38
- Previous Close: $1.12
- Volume: 701.54K
- Average Volume (3M): 2.84M
- Market Cap: $19.19M
- Enterprise Value: $21.10M
- Total Cash (Recent Filing): $609.74K
- Total Debt (Recent Filing): $2.80M
- Price to Earnings (P/E): -0.5
- Beta: 0.38
- Next Earnings: April 10, 2024
- EPS Estimate: N/A
- Next Dividend Ex-Date: N/A
- Dividend Yield: N/A
NVOS stock prediction – Get All the Data
As of December 25, 2023, NVOS stock is at $1.110, in a year-long uptrend. Novo Integrated Sciences shows a strong rising trend, reflecting market popularity.
Our site uses Deep Learning to evaluate NVOS for your portfolio, predicting a potential $171.255 from a $100 investment by December 25, 2024, based on a projected $1.9009250063564 stock price.
Prediction for the stock over the next year
Consider NVOS for your bullish market portfolio. Our prediction system foresees the stock’s future price at $1.9275027260276, indicating a 73.649% increase over the next year.
This implies that if you invest $100 today, your investment could grow to $173.649 by December 24, 2024, which falls on a Tuesday.
Bottom line
In conclusion, NVOS stock is worth exploring, considering its healthcare services and recent developments, such as a 19% share increase following a $60 million acquisition and a strategic collaboration in India.
Current stock statistics include a price of $1.11, a 52-week range of $0.70 – $5.38, a market cap of $19.19M, and a P/E ratio -0.5. However, our prediction system suggests a potential 73.649% increase in NVOS stock to $1.9275 by December 24, 2024.
Remember that this information is provided for reference purposes only, and consider NVOS for your portfolio, particularly in a bullish market.
The post NVOS Stock price prediction, news& historical data appeared first on FinanceBrokerage.
